Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Not just weight loss, GLP-1 drugs like Ozempic can help with 175 conditions; says groundbreaking study
A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond their primary uses. This includes unexpected benefits such as aiding in blood clotting and infections,
11h
on MSN
Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...
Medscape
5h
GLP-1 Benefits, Risks Detailed in ‘Atlas’ Mapping Outcomes
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
1d
Novo Nordisk's GLP-1 Drugs: Health Breakthroughs, Big Buybacks, and Medicare's Price-Cut Threat
From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
TCTMD
1d
European Medicines Agency Investigating GLP-1 Drugs and Eye Disease
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
2d
on MSN
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
4h
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
EatingWell on MSN
21h
6 Common Side Effects from Taking a GLP-1 Medication—and How to Manage Them
If your constipation lasts for more than 3 days, speak with your doctor about options to help. You might need to add a stool ...
1d
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ozempic
Wegovy
Medicare
Eli Lilly and Company
Novo Nordisk
Feedback